Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Urinary Bladder Diseases

ClinicalTrials.gov lists 3,275 trials for Urinary Bladder Diseases or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 66.

MeSH D001745 Urogenital Diseases C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 368 Phase 1/2 Phase 1/2 158 Phase 2 Phase 2 548 Phase 2/3 Phase 2/3 41 Phase 3 Phase 3 292 Phase 4 Phase 4 217 Not applicable Not applicable 895 Observational Observational 748 Phase 1 Phase 1 368 Phase 1/2 Phase 1/2 158 Phase 2 Phase 2 548 Phase 2/3 Phase 2/3 41 Phase 3 Phase 3 292 Phase 4 Phase 4 217 Not applicable Not applicable 895 Observational Observational 748

Trials per phase (log scale)

1 more section with rows

61 of the 3,275 trials are tagged with Urinary Bladder Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Urinary Bladder Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Urinary Bladder Diseases trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 230

1990: 1 trials (Not applicable 1) 1991: 1 trials (Phase 3 1) 1993: 2 trials (Phase 3 1, Phase 2/3 1) 1994: 5 trials (Observational 1, Phase 3 2, Phase 2/3 1, Phase 1 1) 1995: 3 trials (Phase 2/3 1, Phase 2 1, Phase 1/2 1) 1996: 7 trials (Observational 1, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 1997: 9 trials (Observational 1, Phase 3 2, Phase 2 2, Phase 1/2 2, Phase 1 2) 1998: 17 trials (Observational 3, Phase 3 4, Phase 2 7, Phase 1 3) 1999: 20 trials (Observational 2, Phase 4 1, Phase 3 5, Phase 2 6, Phase 1/2 1, Phase 1 5) 2000: 20 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1 6) 2001: 24 trials (Not applicable 1, Phase 3 6, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 5) 2002: 17 trials (Observational 6, Not applicable 1, Phase 3 5, Phase 2 4, Phase 1 1) 2003: 32 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 5, Phase 2 17, Phase 1 5) 2004: 55 trials (Observational 10, Not applicable 7, Phase 4 3, Phase 3 12, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 6) 2005: 61 trials (Observational 14, Not applicable 10, Phase 4 6, Phase 3 8, Phase 2 14, Phase 1/2 5, Phase 1 4) 2006: 77 trials (Observational 11, Not applicable 10, Phase 4 12, Phase 3 8, Phase 2/3 1, Phase 2 23, Phase 1/2 4, Phase 1 8) 2007: 96 trials (Observational 18, Not applicable 7, Phase 4 11, Phase 3 20, Phase 2/3 2, Phase 2 26, Phase 1 12) 2008: 95 trials (Observational 21, Not applicable 15, Phase 4 12, Phase 3 10, Phase 2/3 1, Phase 2 23, Phase 1/2 2, Phase 1 11) 2009: 112 trials (Observational 29, Not applicable 23, Phase 4 15, Phase 3 13, Phase 2/3 2, Phase 2 18, Phase 1/2 3, Phase 1 9) 2010: 89 trials (Observational 24, Not applicable 11, Phase 4 16, Phase 3 8, Phase 2/3 2, Phase 2 17, Phase 1/2 3, Phase 1 8) 2011: 88 trials (Observational 17, Not applicable 17, Phase 4 11, Phase 3 5, Phase 2/3 1, Phase 2 20, Phase 1/2 5, Phase 1 12) 2012: 102 trials (Observational 21, Not applicable 22, Phase 4 10, Phase 3 13, Phase 2/3 1, Phase 2 17, Phase 1/2 4, Phase 1 14) 2013: 98 trials (Other 1, Observational 18, Not applicable 28, Phase 4 10, Phase 3 10, Phase 2/3 2, Phase 2 12, Phase 1/2 6, Phase 1 11) 2014: 126 trials (Observational 27, Not applicable 46, Phase 4 9, Phase 3 7, Phase 2/3 3, Phase 2 19, Phase 1/2 6, Phase 1 9) 2015: 128 trials (Observational 30, Not applicable 31, Phase 4 11, Phase 3 11, Phase 2/3 1, Phase 2 19, Phase 1/2 7, Phase 1 18) 2016: 143 trials (Observational 30, Not applicable 44, Phase 4 8, Phase 3 18, Phase 2/3 1, Phase 2 14, Phase 1/2 7, Phase 1 21) 2017: 151 trials (Observational 46, Not applicable 39, Phase 4 14, Phase 3 5, Phase 2/3 1, Phase 2 21, Phase 1/2 5, Phase 1 20) 2018: 160 trials (Observational 30, Not applicable 56, Phase 4 7, Phase 3 11, Phase 2/3 2, Phase 2 36, Phase 1/2 6, Phase 1 12) 2019: 171 trials (Observational 40, Not applicable 53, Phase 4 7, Phase 3 14, Phase 2/3 2, Phase 2 22, Phase 1/2 13, Phase 1 20) 2020: 181 trials (Observational 54, Not applicable 51, Phase 4 3, Phase 3 7, Phase 2 33, Phase 1/2 6, Phase 1 27) 2021: 230 trials (Observational 70, Not applicable 69, Phase 4 12, Phase 3 15, Phase 2 25, Phase 1/2 19, Phase 1 20) 2022: 179 trials (Observational 52, Not applicable 57, Phase 4 11, Phase 3 10, Phase 2 19, Phase 1/2 12, Phase 1 18) 2023: 196 trials (Observational 54, Not applicable 76, Phase 4 4, Phase 3 10, Phase 2/3 4, Phase 2 24, Phase 1/2 5, Phase 1 19) 2024: 173 trials (Observational 42, Not applicable 65, Phase 4 6, Phase 3 10, Phase 2/3 3, Phase 2 19, Phase 1/2 8, Phase 1 20) 2025: 190 trials (Observational 39, Not applicable 73, Phase 4 9, Phase 3 12, Phase 2/3 4, Phase 2 24, Phase 1/2 11, Phase 1 18)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 182
2025 190
2024 173
2023 196
2022 179
2021 230
2020 181
2019 171
2018 160
2017 151

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 210 trials starting in 2026 and about 200 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 361 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 1,926 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Urinary Bladder Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 368
Phase 1/2 158
Phase 2 548
Phase 2/3 41
Phase 3 292
Phase 4 217
Not applicable 895
Observational 748
Expanded access 8

How many Urinary Bladder Diseases trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 149
Recruiting 439
Enrolling by invitation 21
Active, not recruiting 183
Available 4

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Urinary Bladder Diseases trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 66
Pfizer 49
Astellas Pharma Inc 46
Allergan 33
Merck Sharp & Dohme LLC 23

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Urinary Bladder Diseases? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 76
Tolterodine 48
(nab)-paclitaxel 40
NIVOLUMAB 36
DURVALUMAB 31

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 146
Cisplatin 1 102
Solifenacin PO 79
mirabegron OCAS 75
type A botulinum toxin 49

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Urinary Bladder Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Urinary tract infection 708 87
Pneumonia 487 88
Sepsis 420 97
Acute kidney injury 381 57
Disease progression 301 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Urinary Bladder Diseases? (204)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Transvaginal mesh or grafts or native tissue repair for vaginal prolapse. The Cochrane database of systematic reviews 2024 Yes
Systematic review of urological injury during caesarean section and hysterectomy. International urogynecology journal 2023 Yes
Effectiveness of game-based core exercise in children with non-neuropathic bladder dysfunction and comparison to biofeedback therapy. Lower urinary tract symptoms 2023 Yes
ICS-SUFU standard: Theory, terms, and recommendations for pressure-flow studies performance, analysis, and reporting. Part 1: Background theory and practice. Neurourology and urodynamics 2023 Yes
Acupuncture for treating overactive bladder in adults. The Cochrane database of systematic reviews 2022 Yes

Showing 5 of 204 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (11)

MeSH descendants one level down with at least one trial, most trials first.

+1 more sub-condition

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages